Opinion
Video
Author(s):
A comprehensive discussion surrounding the clinical development of PSMA-targeted therapies for patients with prostate cancer.
Radioligand therapy shows promising safety in patients with mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
Dr. Schwen on focal therapies for prostate cancer
Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC
FDA updates in urology: February 2025